The FDA expanded the approval of Roche’s Alecensa to include adjuvant treatment of non-small cell lung cancer. The targeted therapy addresses cancers driven by the ALK genetic mutation.
The post Roche Drug Scores Label Expansion for Earlier Use in Lung Cancer appeared first on MedCity News.